Stock Events

Stock Events

CERo Therapeutics 

$0.010000
79
-$0.00-9.09% Friday 19:59

Statistics

Day High
0.0104
Day Low
0.0092
52W High
8.8
52W Low
0.008
Volume
1,292,772
Avg. Volume
840,488
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2SepExpected
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-124.26
-83.09
-41.93
-0.76
Expected EPS
-0.7956
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-21.03MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CERO. It's not an investment recommendation.
NVIDIA
7
NVDA
Palantir Technologies
6
PLTR
Microsoft
5
MSFT
Realty Income
5
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics focuses on gene editing technologies, similar to CERo Therapeutics' approach in genetic medicine.
Editas Medicine
EDIT
Mkt Cap500.29M
Editas Medicine works on genome editing using CRISPR, directly competing in the same innovative sector as CERo Therapeutics.
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Intellia Therapeutics is another key player in the CRISPR technology space, making it a direct competitor in gene editing therapies.
Beam Therapeutics
BEAM
Mkt Cap3.36B
Beam Therapeutics also specializes in CRISPR technology, particularly base editing, a method that competes with CERo's gene editing approaches.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics focuses on genomic medicine, including gene editing and gene therapy, areas that overlap with CERo's interests.
Allogene Therapeutics
ALLO
Mkt Cap690.31M
Allogene Therapeutics is involved in allogeneic CAR T-cell therapies, competing in the broader field of innovative cancer treatments like CERo.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical develops gene therapies for genetic diseases, competing with CERo Therapeutics in the genetic medicine market.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a growing interest in gene therapy and biotechnology solutions for health issues, positioning it as a broader competitor.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals engages in several areas including gene editing, making it a competitor in the innovative therapeutic sector.

About

CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
Show more...
CEO
Mr. Christopher B. Ehrlich M.B.A.
Employees
8
Country
United States
ISIN
US71902K4022

Listings

OTC Link
US
CERO
OTC Link
US
CEROW

0 Comments

Share your thoughts

FAQ

What is CERo Therapeutics stock price today?▼
The current price of CERO is $0.01 USD — it has decreased by -9.09% in the past 24 hours. Watch CERo Therapeutics stock price performance more closely on the chart.
What is CERo Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange CERo Therapeutics stocks are traded under the ticker CERO.
Is CERo Therapeutics stock price growing?▼
CERO stock has fallen by -9.09% compared to the previous week, the month change is a -9.09% fall, over the last year CERo Therapeutics has showed a -99.87% decrease.
When is the next CERo Therapeutics earnings date?▼
CERo Therapeutics is going to release the next earnings report on September 02, 2026.
What is CERo Therapeutics revenue for the last year?▼
CERo Therapeutics revenue for the last year amounts to 0 USD.
What is CERo Therapeutics net income for the last year?▼
CERO net income for the last year is -21.03M USD.
How many employees does CERo Therapeutics have?▼
As of July 26, 2026, the company has 8 employees.
In which sector is CERo Therapeutics located?▼
CERo Therapeutics operates in the Health & Wellness sector.
When did CERo Therapeutics complete a stock split?▼
The last stock split for CERo Therapeutics was on June 13, 2025 with a ratio of 1:20.
Where is CERo Therapeutics headquartered?▼
CERo Therapeutics is headquartered in South San Francisco, United States.